Shopping Cart 0
Cart Subtotal
AED 0

ViaCyte Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

ViaCyte Inc (ViaCyte), formerly Novocell Inc is a regenerative medicine company that centres on the development of cell replacement therapies for the treatment of diabetes. The company's pipeline products portfolio includes VC-01, which is being developed as a therapy for T1D patients who have minimal to no insulin-producing beta cell function; and PEC-Direct, for type 1 diabetes patients that have glycemic lability, hypoglycemic episodes, and impaired hypoglycemia awareness. Its PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device. The company works in partnership with academic, commercial and not-for-profit institutions. ViaCyte is headquartered in San Diego, California, the US.

ViaCyte Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ViaCyte Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

ViaCyte Raises USD10 Million in Financing 11

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12

ViaCyte Raises USD15 Million in Venture Financing 13

Partnerships 14

CRISPR Therapeutics and ViaCyte Enter into Co-Development Agreement 14

ViaCyte Enters into Research Agreement with W. L. Gore & Associates 15

Licensing Agreements 16

ViaCyte Enters into Licensing Agreement with Janssen Biotech 16

Takara Bio Enters into Licensing Agreement with ViaCyte 17

ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 18

Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 19

Debt Offering 20

ViaCyte Raises USD10 million in Convertible Promissory Notes 20

ViaCyte Inc-Key Competitors 21

ViaCyte Inc-Key Employees 22

ViaCyte Inc-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Government and Public Interest 24

Apr 17, 2018: ViaCyte Awarded NIH SBIR Grant to Support In Vitro Development of Stem Cell-Derived Functional Human Pancreatic Beta Cells 24

Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 25

Product News 26

05/22/2017: JDRF and ViaCyte Announce Support for Development of PEC-Direct Cell Replacement Therapy for Type 1 Diabetes 26

02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Direct for Type 1 Diabetes 27

02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Encap for insulin-requiring diabetes 28

Product Approvals 29

May 22, 2017: ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes 29

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

ViaCyte Inc, Pharmaceuticals & Healthcare, Key Facts 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ViaCyte Inc, Deals By Therapy Area, 2012 to YTD 2018 8

ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ViaCyte Raises USD10 Million in Financing 11

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12

ViaCyte Raises USD15 Million in Venture Financing 13

CRISPR Therapeutics and ViaCyte Enter into Co-Development Agreement 14

ViaCyte Enters into Research Agreement with W. L. Gore & Associates 15

ViaCyte Enters into Licensing Agreement with Janssen Biotech 16

Takara Bio Enters into Licensing Agreement with ViaCyte 17

ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 18

Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 19

ViaCyte Raises USD10 million in Convertible Promissory Notes 20

ViaCyte Inc, Key Competitors 21

ViaCyte Inc, Key Employees 22

ViaCyte Inc, Subsidiaries 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Company Profile

Company Profile Title

Summary

ViaCyte Inc (ViaCyte), formerly Novocell Inc is a regenerative medicine company that centres on the development of cell replacement therapies for the treatment of diabetes. The company's pipeline products portfolio includes VC-01, which is being developed as a therapy for T1D patients who have minimal to no insulin-producing beta cell function; and PEC-Direct, for type 1 diabetes patients that have glycemic lability, hypoglycemic episodes, and impaired hypoglycemia awareness. Its PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device. The company works in partnership with academic, commercial and not-for-profit institutions. ViaCyte is headquartered in San Diego, California, the US.

ViaCyte Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ViaCyte Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

ViaCyte Raises USD10 Million in Financing 11

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12

ViaCyte Raises USD15 Million in Venture Financing 13

Partnerships 14

CRISPR Therapeutics and ViaCyte Enter into Co-Development Agreement 14

ViaCyte Enters into Research Agreement with W. L. Gore & Associates 15

Licensing Agreements 16

ViaCyte Enters into Licensing Agreement with Janssen Biotech 16

Takara Bio Enters into Licensing Agreement with ViaCyte 17

ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 18

Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 19

Debt Offering 20

ViaCyte Raises USD10 million in Convertible Promissory Notes 20

ViaCyte Inc-Key Competitors 21

ViaCyte Inc-Key Employees 22

ViaCyte Inc-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Government and Public Interest 24

Apr 17, 2018: ViaCyte Awarded NIH SBIR Grant to Support In Vitro Development of Stem Cell-Derived Functional Human Pancreatic Beta Cells 24

Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 25

Product News 26

05/22/2017: JDRF and ViaCyte Announce Support for Development of PEC-Direct Cell Replacement Therapy for Type 1 Diabetes 26

02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Direct for Type 1 Diabetes 27

02/23/2017: Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapy PEC-Encap for insulin-requiring diabetes 28

Product Approvals 29

May 22, 2017: ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes 29

Appendix 31

Methodology 31

About GlobalData 31

Contact Us 31

Disclaimer 31


List Of Figure

List of Figures

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

ViaCyte Inc, Pharmaceuticals & Healthcare, Key Facts 2

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

ViaCyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

ViaCyte Inc, Deals By Therapy Area, 2012 to YTD 2018 8

ViaCyte Inc, Medical Devices Deals, 2012 to YTD 2018 9

ViaCyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ViaCyte Raises USD10 Million in Financing 11

ViaCyte Raises Additional USD5.4 Million in Series C-1 Venture Financing 12

ViaCyte Raises USD15 Million in Venture Financing 13

CRISPR Therapeutics and ViaCyte Enter into Co-Development Agreement 14

ViaCyte Enters into Research Agreement with W. L. Gore & Associates 15

ViaCyte Enters into Licensing Agreement with Janssen Biotech 16

Takara Bio Enters into Licensing Agreement with ViaCyte 17

ViaCyte Enters into Option for Licensing Agreement with Janssen Research & Development 18

Nestle Institute of Health Sciences Enters into Licensing Agreement with ViaCyte 19

ViaCyte Raises USD10 million in Convertible Promissory Notes 20

ViaCyte Inc, Key Competitors 21

ViaCyte Inc, Key Employees 22

ViaCyte Inc, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS